AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More
ASTRAZENECA PHARMA | STERLING BIOTECH | ASTRAZENECA PHARMA/ STERLING BIOTECH |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 129.4 | -0.4 | - | View Chart |
P/BV | x | 36.3 | 0.0 | 254,937.1% | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASTRAZENECA PHARMA Mar-18 |
STERLING BIOTECH Dec-13 |
ASTRAZENECA PHARMA/ STERLING BIOTECH |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,278 | 11 | 12,171.4% | |
Low | Rs | 883 | 3 | 25,958.8% | |
Sales per share (Unadj.) | Rs | 228.4 | 26.8 | 852.0% | |
Earnings per share (Unadj.) | Rs | 10.4 | -15.0 | -69.3% | |
Cash flow per share (Unadj.) | Rs | 16.3 | -5.5 | -297.7% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Dividend yield (eoy) | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 98.8 | 54.9 | 180.0% | |
Shares outstanding (eoy) | m | 25.00 | 267.87 | 9.3% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 4.7 | 0.3 | 1,824.3% | |
Avg P/E ratio | x | 104.2 | -0.5 | -22,432.3% | |
P/CF ratio (eoy) | x | 66.4 | -1.3 | -5,222.1% | |
Price / Book Value ratio | x | 10.9 | 0.1 | 8,636.9% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 27,008 | 1,862 | 1,450.7% | |
No. of employees | `000 | 1.4 | 1.4 | 100.1% | |
Total wages/salary | Rs m | 1,535 | 547 | 280.8% | |
Avg. sales/employee | Rs Th | 4,210.9 | 5,303.3 | 79.4% | |
Avg. wages/employee | Rs Th | 1,132.2 | 403.8 | 280.4% | |
Avg. net profit/employee | Rs Th | 191.1 | -2,959.0 | -6.5% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 5,710 | 7,181 | 79.5% | |
Other income | Rs m | 123 | 43 | 287.6% | |
Total revenues | Rs m | 5,833 | 7,223 | 80.7% | |
Gross profit | Rs m | 463 | 947 | 48.9% | |
Depreciation | Rs m | 147 | 2,543 | 5.8% | |
Interest | Rs m | 0 | 4,377 | 0.0% | |
Profit before tax | Rs m | 438 | -5,931 | -7.4% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 179 | -1,924 | -9.3% | |
Profit after tax | Rs m | 259 | -4,007 | -6.5% | |
Gross profit margin | % | 8.1 | 13.2 | 61.5% | |
Effective tax rate | % | 40.8 | 32.4 | 125.9% | |
Net profit margin | % | 4.5 | -55.8 | -8.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 3,209 | 14,335 | 22.4% | |
Current liabilities | Rs m | 2,070 | 49,809 | 4.2% | |
Net working cap to sales | % | 20.0 | -494.0 | -4.0% | |
Current ratio | x | 1.6 | 0.3 | 538.8% | |
Inventory Days | Days | 72 | 403 | 17.9% | |
Debtors Days | Days | 35 | 171 | 20.5% | |
Net fixed assets | Rs m | 790 | 55,432 | 1.4% | |
Share capital | Rs m | 50 | 268 | 18.7% | |
"Free" reserves | Rs m | 2,419 | 13,935 | 17.4% | |
Net worth | Rs m | 2,469 | 14,701 | 16.8% | |
Long term debt | Rs m | 0 | 9,478 | 0.0% | |
Total assets | Rs m | 4,605 | 73,988 | 6.2% | |
Interest coverage | x | NM | -0.4 | - | |
Debt to equity ratio | x | 0 | 0.6 | 0.0% | |
Sales to assets ratio | x | 1.2 | 0.1 | 1,277.5% | |
Return on assets | % | 5.6 | 0.5 | 1,123.2% | |
Return on equity | % | 10.5 | -27.3 | -38.5% | |
Return on capital | % | 17.7 | -6.4 | -276.0% | |
Exports to sales | % | 0 | 25.9 | 0.0% | |
Imports to sales | % | 0 | 0.2 | 0.0% | |
Exports (fob) | Rs m | NA | 1,860 | 0.0% | |
Imports (cif) | Rs m | NA | 12 | 0.0% | |
Fx inflow | Rs m | 300 | 1,860 | 16.1% | |
Fx outflow | Rs m | 2,015 | 25 | 8,095.3% | |
Net fx | Rs m | -1,715 | 1,835 | -93.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 88 | 1,719 | 5.1% | |
From Investments | Rs m | -94 | -3,148 | 3.0% | |
From Financial Activity | Rs m | NA | 1,426 | 0.0% | |
Net Cashflow | Rs m | -6 | -3 | 167.6% |
Indian Promoters | % | 0.0 | 33.9 | - | |
Foreign collaborators | % | 75.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.3 | 0.0 | - | |
FIIs | % | 15.7 | 9.9 | 158.6% | |
ADR/GDR | % | 0.0 | 16.9 | - | |
Free float | % | 9.1 | 39.3 | 23.2% | |
Shareholders | 12,856 | 21,482 | 59.8% | ||
Pledged promoter(s) holding | % | 0.0 | 55.9 | - |
Compare ASTRAZENECA PHARMA With: STRIDES PHARMA SCIENCE AJANTA PHARMA ALEMBIC ALEMBIC PHARMA CADILA HEALTHCARE
Compare ASTRAZENECA PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.
For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.
More Views on NewsIn this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
The budget is just a few weeks away. Which stocks can you expect to move? Find out in this video.
Select smallcaps hold a great potential to become the multibaggers of tomorrow. Here's how you could get in early into these stocks.
More